Literature DB >> 23685786

T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Esther Bandala-Sanchez1, Yuxia Zhang, Simone Reinwald, James A Dromey, Bo-Han Lee, Junyan Qian, Ralph M Böhmer, Leonard C Harrison.   

Abstract

Functionally diverse T cell populations interact to maintain homeostasis of the immune system. We found that human and mouse antigen-activated T cells with high expression of the lymphocyte surface marker CD52 suppressed other T cells. CD52(hi)CD4(+) T cells were distinct from CD4(+)CD25(+)Foxp3(+) regulatory T cells. Their suppression was mediated by soluble CD52 released by phospholipase C. Soluble CD52 bound to the inhibitory receptor Siglec-10 and impaired phosphorylation of the T cell receptor-associated kinases Lck and Zap70 and T cell activation. Humans with type 1 diabetes had a lower frequency and diminished function of CD52(hi)CD4(+) T cells responsive to the autoantigen GAD65. In diabetes-prone mice of the nonobese diabetic (NOD) strain, transfer of lymphocyte populations depleted of CD52(hi) cells resulted in a substantially accelerated onset of diabetes. Our studies identify a ligand-receptor mechanism of T cell regulation that may protect humans and mice from autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685786     DOI: 10.1038/ni.2610

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  46 in total

Review 1.  Positive and negative regulation of T-cell activation through kinases and phosphatases.

Authors:  Tomas Mustelin; Kjetil Taskén
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

2.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

3.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

Authors:  Tomoko Watanabe; Jun-ichi Masuyama; Yoshiaki Sohma; Hiroko Inazawa; Kaori Horie; Kumiko Kojima; Yasunori Uemura; Yumi Aoki; Shuji Kaga; Seiji Minota; Toshiyuki Tanaka; Yasunori Yamaguchi; Tetsuto Kobayashi; Isao Serizawa
Journal:  Clin Immunol       Date:  2006-06-22       Impact factor: 3.969

4.  Natural ligands for CD33-related Siglecs?

Authors:  Ajit Varki
Journal:  Glycobiology       Date:  2009-05-09       Impact factor: 4.313

Review 5.  Is FOXP3 a bona fide marker for human regulatory T cells?

Authors:  Maria-Grazia Roncarolo; Silvia Gregori
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

Review 6.  Siglecs--the major subfamily of I-type lectins.

Authors:  Ajit Varki; Takashi Angata
Journal:  Glycobiology       Date:  2005-07-13       Impact factor: 4.313

7.  Antibodies to 5'-nucleotidase (CD73), a glycosyl-phosphatidylinositol-anchored protein, cause human peripheral blood T cells to proliferate.

Authors:  L F Thompson; J M Ruedi; A Glass; M G Low; A H Lucas
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

8.  Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.

Authors:  W C Rowan; G Hale; J P Tite; S J Brett
Journal:  Int Immunol       Date:  1995-01       Impact factor: 4.823

9.  CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.

Authors:  Guo-Yun Chen; Jie Tang; Pan Zheng; Yang Liu
Journal:  Science       Date:  2009-03-05       Impact factor: 47.728

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  58 in total

Review 1.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Regulation unmasked by activation.

Authors:  Mike Clark; Anne Cooke
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

3.  Immune regulation by CD52-expressing CD4 T cells.

Authors:  Ban-Hock Toh; Tin Kyaw; Peter Tipping; Alex Bobik
Journal:  Cell Mol Immunol       Date:  2013-08-12       Impact factor: 11.530

4.  CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells.

Authors:  Buka Samten
Journal:  Cell Mol Immunol       Date:  2013-09-16       Impact factor: 11.530

5.  Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface.

Authors:  Marei Sammar; Monika Siwetz; Hamutal Meiri; Viktor Fleming; Peter Altevogt; Berthold Huppertz
Journal:  Histochem Cell Biol       Date:  2016-12-23       Impact factor: 4.304

6.  Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Authors:  Evis Havari; Michael J Turner; Juanita Campos-Rivera; Srinivas Shankara; Tri-Hung Nguyen; Bruce Roberts; William Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

Review 7.  Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.

Authors:  Guo-Yun Chen; Nicholas K Brown; Pan Zheng; Yang Liu
Journal:  Glycobiology       Date:  2014-07-04       Impact factor: 4.313

8.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 10.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.